mixtard
novo nordisk a/s - insulin human - sykursýki - lyf notuð við sykursýki - meðferð sykursýki.
protaphane
novo nordisk a/s - insulin human - sykursýki - lyf notuð við sykursýki - meðferð sykursýki.
vydura
pfizer europe ma eeig - rimegepant - mígreni kvilla - antimigraine preparations, calcitonin gene-related peptide (cgrp) antagonists - vydura is indicated for theacute treatment of migraine with or without aura in adults;preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month.
ticovac stungulyf, dreifa 0,5 ml
pfizer aps - tbe antigen virus - stungulyf, dreifa - 0,5 ml
ticovac junior stungulyf, dreifa 0,25 ml
pfizer aps - tbe antigen virus - stungulyf, dreifa - 0,25 ml
kyleena leginnlegg 19.5 mg
bayer a/s* - levonorgestrelum inn - leginnlegg - 19.5 mg
jaydess leginnlegg 13,5 mg
bayer ab - levonorgestrelum inn - leginnlegg - 13,5 mg
synarela nefúði, lausn 2 mg/ml
pfizer aps - nafarelinum acetat - nefúði, lausn - 2 mg/ml
increxxa
elanco gmbh - túlatrómýsín - sýklalyf til almennrar notkunar - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. tilvist sjúkdómsins í hjörðinni skal komið á áður en meðferð með bráðaofnæmi. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. tilvist sjúkdómsins í hjörðinni skal komið á áður en meðferð með bráðaofnæmi. the product should only be used if pigs are expected to develop the disease within 2–3 days. sauðfé: meðferð á fyrstu stigum smitandi beinbólgu (fótspyrnu) í tengslum við veirufræðilega dichelobacter nodosus sem krefst kerfisbundinnar meðferðar.
upstaza
ptc therapeutics international limited - eladocagene exuparvovec - aminósýra efnaskipti, innfæddir villur - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.